Osteopontin–CD44v6 Interaction Mediates Calcium Deposition via Phospho-Akt in Valve Interstitial Cells From Patients With Noncalcified Aortic Valve Sclerosis
- 1 September 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 34 (9) , 2086-2094
Abstract
Objective—: The activation of valve interstitial cells (VICs) toward an osteogenic phenotype characterizes aortic valve sclerosis, the early asymptomatic phase of calcific aortic valve disease. Osteopontin is a phosphorylated acidic glycoprotein that accumulates within the aortic leaflets and labels VIC activation even in noncalcified asymptomatic patients. Despite this, osteopontin protects VICs against in vitro calcification. Here, we hypothesize that the specific interaction of osteopontin with CD44v6, and the related intracellular pathway, prevents calcium deposition in human-derived VICs from patients with aortic valve sclerosis. Approach and Results—: On informed consent, 23 patients and 4 controls were enrolled through the cardiac surgery and heart transplant programs. Human aortic valves and VICs were tested for osteogenic transdifferentiation, ex vivo and in vitro. Osteopontin–CD44 interaction was analyzed using proximity ligation assay and the signaling pathways investigated. A murine model based on angiotensin II infusion was used to mimic early pathological remodeling of the aortic valves. We report osteopontin–CD44 functional interaction as a hallmark of early stages of calcific aortic valve disease. We demonstrated that osteopontin–CD44 interaction mediates calcium deposition via phospho-Akt in VICs from patients with noncalcified aortic valve sclerosis. Finally, microdissection analysis of murine valves shows increased cusp thickness in angiotensin II-treated mice versus saline infused along with colocalization of osteopontin and CD44 as seen in human lesions. Conclusions—: Here, we unveil a specific protein–protein association and intracellular signaling mechanisms of osteopontin. Understanding the molecular mechanisms of early VIC activation and calcium deposition in asymptomatic stage of calcific aortic valve disease could open new prospective for diagnosis and therapeutic intervention.Keywords
This publication has 75 references indexed in Scilit:
- Analysis of Osteopontin Levels for the Identification of Asymptomatic Patients With Calcific Aortic Valve DiseaseThe Annals of Thoracic Surgery, 2012
- ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart diseaseEuropean Heart Journal, 2011
- Polymorphic variants in tenascin-C (TNC) are associated with atherosclerosis and coronary artery diseaseHuman Genetics, 2011
- Osteopontin controls endothelial cell migration in vitro and in excised human valvular tissue from patients with calcific aortic stenosis and controlsJournal of Cellular Physiology, 2010
- Validation of Plasma Biomarkers in Degenerative Calcific Aortic StenosisJournal of Surgical Research, 2010
- Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE−/− miceClinical Science, 2010
- Statins Block Calcific Nodule Formation of Valvular Interstitial Cells by Inhibiting α-Smooth Muscle Actin ExpressionArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic miceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Osteopontin Promoter Polymorphism Is Associated With Increased Carotid Intima-Media ThicknessJournal of the American Society of Echocardiography, 2008
- Synergistic effects of cyclic tension and transforming growth factor-β1 on the aortic valve myofibroblastCardiovascular Pathology, 2007